Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy

NCT03066076

Graves Disease Graves Ophthalmopathy Graves' Ophthalmopathy Worsened

UNKNOWN PHASE3

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

NCT01114503

Graves Ophthalmopathy

TERMINATED PHASE2

Rituximab (RTX) Therapy in Patients With Active TAO

NCT02378298

Ophthalmopathy, Thyroid-Associated

COMPLETED PHASE4

Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy

NCT00424151

Graves' Dysthyroid Ophthalmopathy Thyroid Related Orbitopathy

COMPLETED PHASE1/PHASE2

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867

Thyroid Eye Disease Graves' Orbitopathy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graves' Ophthalmopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carbimazole, radio-active iodine (I131)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion Criteria

* Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
* Age \< 18 years
* Inability to consent to participation in the study
* Pregnancy
* History of radio-active iodine therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No